GRAIL vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
GRAIL develops multi-cancer early detection Galleri test using cell-free DNA methylation to detect signals from 50+ cancer types in a single blood draw; spun off from Illumina in 2024; NHS-Galleri trial enrolling 140,000 participants in the UK.
About
GRAIL is a healthcare company founded in 2016 as an Illumina spinout focused on developing multi-cancer early detection tests using liquid biopsy technology. The company's flagship product Galleri is a blood test that analyzes cell-free DNA methylation patterns to detect cancer signals from over 50 cancer types, many of which lack standard screening tests, enabling detection at early stages when treatment is most effective. GRAIL raised over $3.5B from investors including Amazon and Bristol Myers Squibb and was reacquired by Illumina in 2021 before being spun off again in 2024 as an independent public company following regulatory complications. Galleri has been launched commercially and is being evaluated in large clinical studies including the NHS-Galleri trial in the UK enrolling 140,000 participants. The company represents a transformative approach to oncology that could shift cancer care from reactive treatment toward proactive screening. GRAIL's technology addresses a massive unmet need given that the majority of cancers are diagnosed at late stages when outcomes are poor.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.